IBS C News and Research

RSS

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Overgrowth of bacteria in the gut linked to IBS

An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold standard" method of connecting bacteria to the cause of the disease that affects an estimated 30 million people in the United States.

28 May 2012

Bacteria are key contributors to the cause of IBS, study confirms

25 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

Latest science reveals Australians need to swallow some grains of truth about staple foods

A new report has revealed that the simplification of complex nutritional messages has resulted in grain foods like bread and pasta becoming the ‘scapegoat’ for weight gain and bloating, despite ample research to the contrary.

9 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

Specific proteins can help identify patients with IBS

Irritable bowel syndrome (IBS) is hard to diagnose as well as treat, but researchers at the Sahlgrenska Academy, at the University of Gothenburg, Sweden, have discovered a way of confirming the disorder using stool samples.

8 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

FDA extends review period for linaclotide NDA to treat constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

23 Apr 2012

Women with IBS more likely to suffer from ectopic pregnancies, miscarriages

A study by researchers at University College Cork, Ireland and the University of Manchester, UK suggests that women with Irritable Bowel Syndrome are more likely to suffer from miscarriages and ectopic pregnancies.

4 Apr 2012

Hypnotherapy effective for treating bowel disorder IBS

Hypnosis can be a highly effective treatment for the bowel disorder IBS. Studies involving a total of 346 patients conducted by researchers at The Sahlgrenska Academy of the University of Gothenburg, Sweden, showed that hypnotherapy alleviated symptoms in 40 per cent of those affected - and that the improvement is long-term.

2 Apr 2012

Patients with IBS have higher prevalence of early adverse life events

Patients with irritable bowel syndrome (IBS) have a significantly greater prevalence of early adverse life events , including general trauma as well as physical, emotional and sexual abuse, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Mar 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

Gluten-free diet more of a fad than absolute necessity for many

Many people claim that gluten sensitivity is on the rise and consequently gluten-free products are more popular than ever. A study explores whether shunning gluten is really necessary and finds that in most cases it is not.

22 Feb 2012

Clear link between marijuana use in young males and cyclic vomiting syndrome

Researchers have found clear associations between marijuana use in young males and cyclic vomiting syndrome (CVS), where patients experience episodes of vomiting separated by symptom free intervals.

9 Jan 2012

Psychological problems can influence patient's viewpoint of IBS symptom severity

A patient's viewpoint of the severity of irritable bowel syndrome (IBS) symptoms can be influenced not only by physical symptoms of IBS but broader psychological problems, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

22 Nov 2011

VSL#3 classified as refrigerated medical food for three GI conditions

As clinical studies continue to validate the use of probiotics to help promote general gastrointestinal health, a growing U.S. market for probiotics indicates that the U.S. healthcare community and consumers alike are recognizing the value of these beneficial microorganisms. However, because most probiotics are classified as dietary supplements, directing patients to the best probiotic for their individual needs can be challenging.

18 Nov 2011